Literature DB >> 17185596

Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans.

Katia Koelle1, Sarah Cobey, Bryan Grenfell, Mercedes Pascual.   

Abstract

Human influenza A (subtype H3N2) is characterized genetically by the limited standing diversity of its hemagglutinin and antigenically by clusters that emerge and replace each other within 2 to 8 years. By introducing an epidemiological model that allows for differences between the genetic and antigenic properties of the virus's hemagglutinin, we show that these patterns can arise from cluster-specific immunity alone. Central to the formulation is a genotype-to-phenotype mapping, based on neutral networks, with antigenic phenotypes, not genotypes, determining the degree of strain cross-immunity. The model parsimoniously explains well-known, as well as previously unremarked, features of interpandemic influenza dynamics and evolution. It captures the observed boom-and-bust pattern of viral evolution, with periods of antigenic stasis during which genetic diversity grows, and with episodic contraction of this diversity during cluster transitions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185596     DOI: 10.1126/science.1132745

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  212 in total

1.  Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions.

Authors:  Virginia E Pitzer; Manish M Patel; Ben A Lopman; Cécile Viboud; Umesh D Parashar; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

2.  Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza.

Authors:  Nimalan Arinaminpathy; Oliver Ratmann; Katia Koelle; Suzanne L Epstein; Graeme E Price; Cecile Viboud; Mark A Miller; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-07       Impact factor: 11.205

3.  Mapping of H3N2 influenza antigenic evolution in China reveals a strategy for vaccine strain recommendation.

Authors:  Xiangjun Du; Libo Dong; Yu Lan; Yousong Peng; Aiping Wu; Ye Zhang; Weijuan Huang; Dayan Wang; Min Wang; Yuanji Guo; Yuelong Shu; Taijiao Jiang
Journal:  Nat Commun       Date:  2012-02-28       Impact factor: 14.919

4.  Pathways to extinction: beyond the error threshold.

Authors:  Susanna C Manrubia; Esteban Domingo; Ester Lázaro
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

5.  A two-tiered model for simulating the ecological and evolutionary dynamics of rapidly evolving viruses, with an application to influenza.

Authors:  Katia Koelle; Priya Khatri; Meredith Kamradt; Thomas B Kepler
Journal:  J R Soc Interface       Date:  2010-03-24       Impact factor: 4.118

6.  Synthesizing within-host and population-level selective pressures on viral populations: the impact of adaptive immunity on viral immune escape.

Authors:  Igor Volkov; Kim M Pepin; James O Lloyd-Smith; Jayanth R Banavar; Bryan T Grenfell
Journal:  J R Soc Interface       Date:  2010-03-24       Impact factor: 4.118

7.  Mutational effects and population dynamics during viral adaptation challenge current models.

Authors:  Craig R Miller; Paul Joyce; Holly A Wichman
Journal:  Genetics       Date:  2010-11-01       Impact factor: 4.562

8.  Evolution, safety, and highly pathogenic influenza viruses.

Authors:  Marc Lipsitch; Joshua B Plotkin; Lone Simonsen; Barry Bloom
Journal:  Science       Date:  2012-06-22       Impact factor: 47.728

9.  The effects of a deleterious mutation load on patterns of influenza A/H3N2's antigenic evolution in humans.

Authors:  Katia Koelle; David A Rasmussen
Journal:  Elife       Date:  2015-09-15       Impact factor: 8.140

10.  Adequacy of SEIR models when epidemics have spatial structure: Ebola in Sierra Leone.

Authors:  Wayne M Getz; Richard Salter; Whitney Mgbara
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-06-24       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.